Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2020-01-24 Capital/Financing Update
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It includes details about securities to be registered, offering price, selling security holder, and other information typical of a registration statement for a securities offering. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to capital raising and securities registration. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement, but a substantive filing related to capital raising.
2020-01-24 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details entry into material definitive agreements related to investor financing transactions, including securities purchase agreements and convertible promissory notes. It also includes information about creation of direct financial obligations and unregistered sales of equity securities. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing financing transactions and related agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (11,710 characters) and detailed content support this classification with high confidence.
2020-01-17 English
Regulatory Filings 2019
Regulatory Filings Classification · 80% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of discernible information and the inability to identify the nature of the document, it cannot be classified into any specific filing category. According to the fallback rule, documents that do not fit into any specific category should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable.
2019-12-19 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration statement under the Securities Act of 1933, used by companies planning an initial public offering (IPO) or other securities offering. The text includes detailed information about the securities being registered, the selling security holder, offering price, risk factors, use of proceeds, and other disclosures typical of a prospectus. This is not an annual report, earnings release, or any other financial report but a registration statement for capital raising. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Since this is a registration statement for securities offering, it fits best under CAP.
2019-12-12 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2019-11-14 English
Annual Report 2019
Annual Report FY 2019
2019-10-15 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.